ΑD			

Award Number: W81XWH-04-1-0244

TITLE: The Role of the ADAM-15 Disintegrin in E-Cadherin Proteolysis and Prostate

Cancer Metastasis

PRINCIPAL INVESTIGATOR: Dr. Mark L. Day

CONTRACTING ORGANIZATION: University of Michigan

Ann Arbor, MI 48109-1274

REPORT DATE: February 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently

	OT RETURN YOUR FORM TO THE ABOVE ADDRESS.	
1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
01-02-2006	Annual	20 Jan 2005 – 19 Jan 2006
4. TITLE AND SUBTITLE		5a, CONTRACT NUMBER
4. III EE AND GODIII EE		Ga. CONTINACT NOMBER
The Role of the ADAM-15	5b. GRANT NUMBER	
Metastasis	,	W81XWH-04-1-0244
Wetastasis		5c. PROGRAM ELEMENT NUMBER
		SC. I ROSKAM ELEMENT NOMBER
6. AUTHOR(S)		5d. PROJECT NUMBER
Dr. Mork J. Dov		5e. TASK NUMBER
Dr. Mark L. Day		SE. TASK NOMBER
		5f. WORK UNIT NUMBER
7 DEDECORMING OPGANIZATION	ON NAME(S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT
7.1 EKI OKIMING OKOANIZATI	SIT ITAMIE(O) AND ADDITEOO(EO)	NUMBER
Liniversity of Michigan		HOMBER
University of Michigan		
Ann Arbor, MI 48109-127	4	
9. SPONSORING / MONITORING	G AGENCY NAME(S) AND ADDRESS(ES)	10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Resear	ch and Materiel Command	
Fort Detrick, Maryland 217		
Tort Detrick, Maryland 21	02-3012	44 000000000000000000000000000000000000
		11. SPONSOR/MONITOR'S REPORT
		NUMBER(S)
12. DISTRIBUTION / AVAILABII	ITV CTATEMENT	
	-	
T Approved for Public Relea	se; Distribution Unlimited	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
T P T T T T T T T T		
13. SUPPLEMENTARY NOTES	alata All DTIO assault of a same illustration and a literature	
13. SUPPLEMENTARY NOTES	plates: ALL DTIC reproductions will be in black and white.	
13. SUPPLEMENTARY NOTES	plates: ALL DTIC reproductions will be in black and white.	
13. SUPPLEMENTARY NOTES Original contains colored	plates: ALL DTIC reproductions will be in black and white.	
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT	· · · · · · · · · · · · · · · · · · ·	prostate cancer. Importantly, the
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown	that ADAM15 is predominantly overexpressed in metastation	
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific	ation in metastatic prostate cancer,
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific	ation in metastatic prostate cancer,
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a sti	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific ong candidate in the malignant progression of this disease.	cation in metastatic prostate cancer, Our preliminary data strongly suggests
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this pr	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplificiong candidate in the malignant progression of this disease. otein in the growth, angiogenesis and metastatic progression.	ation in metastatic prostate cancer, Our preliminary data strongly suggests n of prostate cancer. Previous research
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific rong candidate in the malignant progression of this disease. otein in the growth, angiogenesis and metastatic progressiof ADAM15 in vascular endothelial biology with clear implication.	ation in metastatic prostate cancer, Our preliminary data strongly suggests n of prostate cancer. Previous research tions in endothelial interaction and
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplificiong candidate in the malignant progression of this disease. otein in the growth, angiogenesis and metastatic progression.	ation in metastatic prostate cancer, Our preliminary data strongly suggests n of prostate cancer. Previous research tions in endothelial interaction and
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of angiogenesis. However, the	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplification cong candidate in the malignant progression of this disease otein in the growth, angiogenesis and metastatic progression of ADAM15 in vascular endothelial biology with clear implicate specific actions of ADAM15 in tumor epithelium and influence.	ation in metastatic prostate cancer, Our preliminary data strongly suggests n of prostate cancer. Previous research tions in endothelial interaction and ences on neighboring endothelial cells in
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of angiogenesis. However, the tumor microenvironme	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplification cong candidate in the malignant progression of this disease. Otein in the growth, angiogenesis and metastatic progression of ADAM15 in vascular endothelial biology with clear implicate specific actions of ADAM15 in tumor epithelium and influent have not been explored. The continuing studies, if successions	action in metastatic prostate cancer, Our preliminary data strongly suggests on of prostate cancer. Previous research tions in endothelial interaction and ences on neighboring endothelial cells in esful, will not only confirm the role of
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of angiogenesis. However, the tumor microenvironme ADAM15 in the malignant	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific rong candidate in the malignant progression of this disease. Otein in the growth, angiogenesis and metastatic progression of ADAM15 in vascular endothelial biology with clear implicate specific actions of ADAM15 in tumor epithelium and influent have not been explored. The continuing studies, if successprocesses of prostate tumorigenesis and progression, but we	action in metastatic prostate cancer, Our preliminary data strongly suggests on of prostate cancer. Previous research tions in endothelial interaction and ences on neighboring endothelial cells in esful, will not only confirm the role of
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of angiogenesis. However, the tumor microenvironme ADAM15 in the malignant	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplification cong candidate in the malignant progression of this disease. Otein in the growth, angiogenesis and metastatic progression of ADAM15 in vascular endothelial biology with clear implicate specific actions of ADAM15 in tumor epithelium and influent have not been explored. The continuing studies, if successions	action in metastatic prostate cancer, Our preliminary data strongly suggests on of prostate cancer. Previous research tions in endothelial interaction and ences on neighboring endothelial cells in esful, will not only confirm the role of
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of angiogenesis. However, the tumor microenvironme ADAM15 in the malignant	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific rong candidate in the malignant progression of this disease. Otein in the growth, angiogenesis and metastatic progression of ADAM15 in vascular endothelial biology with clear implicate specific actions of ADAM15 in tumor epithelium and influent have not been explored. The continuing studies, if successprocesses of prostate tumorigenesis and progression, but we	action in metastatic prostate cancer, Our preliminary data strongly suggests on of prostate cancer. Previous research tions in endothelial interaction and ences on neighboring endothelial cells in esful, will not only confirm the role of
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of angiogenesis. However, the tumor microenvironme ADAM15 in the malignant	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific rong candidate in the malignant progression of this disease. Otein in the growth, angiogenesis and metastatic progression of ADAM15 in vascular endothelial biology with clear implicate specific actions of ADAM15 in tumor epithelium and influent have not been explored. The continuing studies, if successprocesses of prostate tumorigenesis and progression, but we	action in metastatic prostate cancer, Our preliminary data strongly suggests on of prostate cancer. Previous research tions in endothelial interaction and ences on neighboring endothelial cells in esful, will not only confirm the role of
13. SUPPLEMENTARY NOTES Original contains colored 14. ABSTRACT Our laboratory has shown chromosomal location of A makes this disintegrin a straberrant function of this prindicates functional roles of angiogenesis. However, the tumor microenvironme ADAM15 in the malignant	that ADAM15 is predominantly overexpressed in metastatic DAM15 on 1q21, a region of specific and high-level amplific rong candidate in the malignant progression of this disease. Otein in the growth, angiogenesis and metastatic progression of ADAM15 in vascular endothelial biology with clear implicate specific actions of ADAM15 in tumor epithelium and influent have not been explored. The continuing studies, if successprocesses of prostate tumorigenesis and progression, but we	action in metastatic prostate cancer, Our preliminary data strongly suggests on of prostate cancer. Previous research tions in endothelial interaction and ences on neighboring endothelial cells in esful, will not only confirm the role of

15. SUBJECT TERMS

metastasis, prostate

16. SECURITY CLAS	SSIFICATION OF:			18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	υυ	6	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	4
Key Research Accomplishments	5
Reportable Outcomes	6
Conclusions	6
References	
Appendices	

INTRODUCTION

A key determinant in the metastatic progression of prostate cancer is the dissociation of cancer cells from the primary tumor that may result from inadequate cell adhesion. In tumors of epithelial origin, the disruption of cellular adhesion appears to arise, in part, through alterations of the E-cadherin cell-adhesion system. In our original proposal we hypothesized that the disintegrin metalloproteinase, ADAM 15, is closely associated with the metastatic progression of prostate cancer and could possibly cleave E-cadherin into proteolytic fragments. Examination of both cDNA and tumor microarrays demonstrated increased expression of ADAM-15 in metastatic prostate cancer. It was also important to note that the chromosomal location for ADAM-15, on 1q21, is a region of specific highlevel amplification in prostate cancer metastasis. Taken together, this information provided a compelling rationale for the proposed studies and supports our central hypothesis: ADAM-15 specifically targets the extracellular domain of E-cadherin and disrupts the adhesive integrity of epithelium during the metastatic progression of prostate cancer. Not only will the proposed studies address the functional role of ADAM-15 in the metastatic transformation of prostate epithelial cells; these results may also justify future studies pursuing ADAM-15 as a direct therapeutic target for metastatic prostate cancer.

BODY:

Over-expression of ADAM15 in minimally malignant prostate epithelial cells to determine if this over-expression cleaves E-cadherin and induces a malignant

phenotype. The intent of aim 1 was to achieve stable high-level expression of ADAM15 in LNCaP cell line and determine if ADAM15 elevation induces E-cadherin cleavage as well as a malignant phenotype in this minimally malignant prostate cancer cell line. ADAM15 was tagged with GFP on its C-terminus and transfected into LNCaP cells. ADAM15-GFP over-expressing LNCaP cells were verified via western blotting and immunohistochemistry by our laboratory (Figure 1). The inactive precursor form of ADAM15 is a 110 kDa protein which is converted into the 90 kDa

active form by the pro-protein convertase furin. We will use the stable LNCaP cell lines (LNCaP ADAM15-GFP) to perform cell motility, invasion and anchorage-independence assays to determine malignant potential of theses cell lines.




Figure 1. ADAM15-GFP LNCaP Cells. LNCaP cells were transfected with vector-GFP or ADAM15-GFP vector constructs. (A) Western blot showing the exogenous ADAM15-GFP in ADAM15-GFP transfected LNCaP cells. (B) Immunocytochemistry showing membranous staining (arrow) of ADAM15 in LNCaP cells.

To determine if ADAM15 knockdown reduces the cleavage of E-cadherin as well as the metastatic phenotype of highly aggressive prostate cancer cells. The results from aim 1 may indicate the ADAM15 promotes a malignant phenotype; however this does not confirm that ADAM15 is directly inducing this phenotype. Thus, the intent of this aim is to confirm that ADAM15 is specifically inducing the malignant phenotype seen by using reverse genetics. To accomplish this task, we will utilize small interfering (si)-RNA-mediated knockdown of ADAM15 using a short hairpin (sh)-RNA construct. We have permanently reduced ADAM15 expression in PC3 cells using ADAM15 siRNA oligos in a lentiviral system. To directly assess the contribution of ADAM15 to prostate tumorigenesis, we examined the ability of ADAM15 knock down cells (shA15PC-3^{luc}) cells to grow as subcutaneous tumor in male SCID mice. Following injection of shA15PC-3^{luc} cells and vector control (vecPC-3^{luc}) cells into both flanks of 5 mice per cell line, we could demonstrate a dramatic reduction in tumor growth starting at 3 weeks using the bioluminescence (figure 2). This experiment demonstrates the utility of our luciferase-based PC-3 tumor system and the ability to monitor tumor growth and progression in live animals.




Figure 2. siRNA knock of ADAM15 inhibits in vivo PC-3 Tumor Growth. shA15PC-3^{luc} and vecPC-3^{luc} tumor growth was monitored over 8 weeks by bioluminescence and plotted as photons per second. At the end of 8 weeks the host animals were euthanized and the tumors excised for gross weight and volume measurements.

ACCOMPLISHMENTS:

- 1. ADAM15-GFP constructs were completed and successfully expressed in LNCAP cells.
- 2. Small interfering (si)-RNA-mediated knockdown of ADAM15 has been achieved as stable expression using viral vectors.
- 3. We have confirmed function of ADAM15 by demonstrating dramatic tumor reduction in vivo of ADAM15 knockdown PC-3 tumors.

REPORTABLE OUTCOMES:

We have created several cell lines that express ADAM15-GFP and have successfully knocked down ADAM15 expression in PC-3 cells. Initial in vivo results indicate that ADAM15 does indeed play a tumor promoting role in prostate cancer.

Abdo Najy who is a graduate student in my lab received a DOD predoctoral fellowship that will cover his salary and tuition through the remainder of this project.

We have a manuscript in press at Neoplasia that is the first comprehensive study of ADAM15 in prostate cancer. The DOD is cited as the funding source.

CONCLUSIONS:

In summary this study to date has yielded two important categories of information:

- 1. Necessary reagents for the remainder of the study are being generated and versified.
- 2. The clinical data examining the expression of ADAM15 in prostate cancer has been published and represents a solid translational platform with which to build the functional studies.